The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

abstract：:Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or surviva...

journal_title：Seminars in oncology

authors： Loprinzi CL,Ellison NM,Goldberg RM,Michalak JC,Burch PA

更新日期：1990-12-01 00:00:00

abstract：:Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

journal_title：Seminars in oncology

authors： Mathew R,Messina JL

更新日期：2012-04-01 00:00:00

abstract：:Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...

journal_title：Seminars in oncology

authors： Ryan CW,Stadler WM,Vogelzang NJ

更新日期：2001-08-01 00:00:00

abstract：:Therapy for metastatic breast cancer can palliate disease and prolong life, but cannot cure. New drugs will be required if this is to change. Cisplatin and its analogue carboplatin offer new approaches to the treatment of metastatic breast cancer. Cisplatin has significant single-agent, front-line activity in metastat...

journal_title：Seminars in oncology

authors： Sledge GW Jr

更新日期：1992-02-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

journal_title：Seminars in oncology

authors： Strope JD,Chau CH,Figg WD

更新日期：2020-10-01 00:00:00

abstract：:Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

journal_title：Seminars in oncology

authors： Armand JP

更新日期：1996-02-01 00:00:00

abstract：:Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

journal_title：Seminars in oncology

authors： Pui CH,Thiel E

更新日期：2009-08-01 00:00:00

abstract：:The medical treatment of squamous cell cervical carcinoma is receiving increasing attention. Cisplatin and ifosfamide are known effective drugs. Paclitaxel has been tested with interesting results in cervical cancer. We evaluated the toxic effects and the antitumor activity of a multiagent regimen that included paclit...

journal_title：Seminars in oncology

authors： Zanetta G,Fei F,Mangioni C

更新日期：2000-02-01 00:00:00

abstract：:Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

journal_title：Seminars in oncology

authors： Rishi A,Goggins M,Wood LD,Hruban RH

更新日期：2015-02-01 00:00:00

abstract：:Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cance...

journal_title：Seminars in oncology

authors： Lazzeroni M,DeCensi A

更新日期：2016-02-01 00:00:00

abstract：:Currently, the primary use of liver transplantation in the setting of malignancy is in patients with hepatocellular carcinoma, with generally accepted criteria for transplantation consisting of the presence of one nodule less than 5 cm or two of three nodules each less than 3 cm in the absence of detectable vascular i...

journal_title：Seminars in oncology

authors： Belghiti J

更新日期：2005-12-01 00:00:00

abstract：:Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

journal_title：Seminars in oncology

authors： Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

更新日期：2003-10-01 00:00:00

abstract：:As antineoplastic therapy improves, patients with cancer will have the potential for prolonged survival. Tumor products may produce metabolic complications, such as hypercalcemia, hyponatremia, and hypoglycemia, and these conditions must be promptly recognized so that treatment can be initiated before severe or life-t...

journal_title：Seminars in oncology

authors： Silverman P,Distelhorst CW

更新日期：1989-12-01 00:00:00

abstract：:Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide variety of human tumors and can lead to increased susceptibility to mTOR inhibitors. Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor typ...

journal_title：Seminars in oncology

authors： Dancey JE,Curiel R,Purvis J

更新日期：2009-12-01 00:00:00

abstract：:Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

journal_title：Seminars in oncology

authors： Ritch PS

更新日期：1990-04-01 00:00:00

abstract：:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

journal_title：Seminars in oncology

authors： Rummel MJ,Mitrou PS,Hoelzer D

更新日期：2002-08-01 00:00:00

abstract：:Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...

journal_title：Seminars in oncology

authors： Loehrer PJ Sr

更新日期：1992-12-01 00:00:00

abstract：:This article reviews the associations of cancer with rheumatic diseases. Recent epidemiologic data linking the autoimmune connective tissue diseases with malignancy will be emphasized. Reports linking the occurrence of malignancy with rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy...

journal_title：Seminars in oncology

authors： Carsons S

更新日期：1997-06-01 00:00:00

abstract：:Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

journal_title：Seminars in oncology

authors： Stoehlmacher J,Lenz HJ

更新日期：2003-06-01 00:00:00

abstract：:Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

journal_title：Seminars in oncology

authors： Creemers GJ

更新日期：1997-12-01 00:00:00

abstract：:Most important is the physician's attitude, energy, and skill focused toward helping the patient through the difficulties in the last weeks of life. Many causes of nausea, dyspnea, and other troublesome symptoms can be effectively treated, and pharmacologic palliation is nearly always possible. A multidisciplinary tea...

journal_title：Seminars in oncology

authors： Storey P

更新日期：1994-12-01 00:00:00

abstract：:The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrand...

journal_title：Seminars in oncology

authors： Bunn PA Jr,Greco FA,Einhorn L

更新日期：1986-09-01 00:00:00

abstract：:Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown a...

journal_title：Seminars in oncology

authors： Schiller JH

更新日期：1999-04-01 00:00:00

abstract：:The primary element involved in the practical delivery of hereditary cancer risk counseling is the development of a cancer genetics service. This service should involve a multidisciplinary core of specialists, aim to identify at-risk individuals and their families, and provide comprehensive genetic counseling with the...

journal_title：Seminars in oncology

authors： DeMarco TA,Smith KL,Nusbaum RH,Peshkin BN,Schwartz MD,Isaacs C

更新日期：2007-10-01 00:00:00

abstract：:Lymphomas of the head and neck arise in Waldeyer's ring, the salivary glands, nasal cavity, paranasal sinuses, thyroid gland, and orbit. Though anatomically in close proximity, lymphomas arising in these sites have distinct clinical characteristics. Factors that appear to influence the pattern of disease include concu...

journal_title：Seminars in oncology

authors： Yuen A,Jacobs C

更新日期：1999-06-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not c...

journal_title：Seminars in oncology

authors： Vose JM,Bierman PJ,Armitage JO

更新日期：1990-12-01 00:00:00

abstract：:Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

journal_title：Seminars in oncology

authors： Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

更新日期：2017-02-01 00:00:00

abstract：:The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer. More recently, interest has focused on the potential of nonplatinum combi...

journal_title：Seminars in oncology

authors： Georgoulias V,Scagliotti G,Miller V,Eckardt J,Douillard JY,Manegold C

更新日期：2001-02-01 00:00:00